Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
West · California
Local context for Wegovy, Ozempic, Mounjaro, and Zepbound in San Francisco (810,000 residents, 4,570,000 metro). UCSF runs leading endocrinology and obesity-medicine programs; Medi-Cal covers T2D GLP-1s with prior auth.
Availability and prices vary by pharmacy and date. We do not maintain real-time per-pharmacy stock data. Confirm with pharmacies directly.
Wegovy
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for chronic weight management in adults and adolescents.
Wegovy in San Francisco →
Ozempic
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for adults with type 2 diabetes.
Ozempic in San Francisco →
Mounjaro
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for adults with type 2 diabetes.
Mounjaro in San Francisco →
Zepbound
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for chronic weight management and obstructive sleep apnea.
Zepbound in San Francisco →
San Francisco is a west-region city with a population of 810,000 (4,570,000 in the broader metropolitan area). California expanded Medicaid under the Affordable Care Act, which means low-income adults can typically qualify for GLP-1 coverage for type 2 diabetes if the state Medicaid program lists the drug.
Statewide, notable health systems include Kaiser Permanente, UCSF, Stanford Health, UCLA Health, Cedars-Sinai.
California's Medicaid program is Medi-Cal. Coverage rules for GLP-1 medications vary by drug and indication; see our pricing by state map and payer-coverage guides for details.
Cities of similar size with comparable healthcare markets.